Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL
1. Pirtobrutinib shows significant improvement in progression-free survival for CLL patients. 2. Third positive Phase 3 trial for pirtobrutinib enhances its endorsement. 3. Global regulatory submissions for pirtobrutinib expansion planned by year-end. 4. Safety profile consistent with previous trials, encouraging for future approvals. 5. Results bolster pirtobrutinib's position as a key oncology treatment option.